Related CAS #
1307293-62-4 (free base)
Risuteganib TFA
Synonym
Risuteganib TFA salt; ALG-1001; ALG1001; ALG 1001;
IUPAC/Chemical Name
glycyl-L-arginylglycyl(sulfo)-D-alanyl-L-threonyl-L-proline compound with 2,2,2-trifluoroacetic acid (1:1)
InChi Key
WLTGXURCDLTUBR-CIEQAUARSA-N
InChi Code
InChI=1S/C22H39N9O11S.C2HF3O2/c1-11(32)17(20(37)31-7-3-5-14(31)21(38)39)30-19(36)13(10-43(40,41)42)29-16(34)9-27-18(35)12(28-15(33)8-23)4-2-6-26-22(24)25;3-2(4,5)1(6)7/h11-14,17,32H,2-10,23H2,1H3,(H,27,35)(H,28,33)(H,29,34)(H,30,36)(H,38,39)(H4,24,25,26)(H,40,41,42);(H,6,7)/t11-,12+,13+,14+,17+;/m1./s1
SMILES Code
N=C(NCCC[C@@H](C(NCC(N[C@H](C(N[C@H](C(N1[C@H](C(O)=O)CCC1)=O)[C@@H](C)O)=O)CS(O)(=O)=O)=O)=O)NC(CN)=O)N.OC(C(F)(F)F)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Risuteganib (400 µM) protects against hydroquinone-induced necrosis and apoptosis, as well as inhibits hydroquinone-induced production of reactive oxygen species (ROS), in human retinal pigment epithelial (RPE) cells. It decreases the expression of BAX, VEGFA, and ITB1 in human age-related macular degeneration (AMD) cybrid cell lines when used at a concentration of 20 mg/ml.3 Risuteganib arrests aberrant blood vessel growth mediated by αVβ3, αVβ5, and α5β1 integrins in vivo.
In vitro activity:
Risuteganib reduced oxidative stress-induced toxicity in two retinal cell lines. Risuteganib protected cultured human retinal pigment epithelium and Müller cell lines against hydrogen peroxide-induced cell death. It mitigated associated transcriptome changes in biological processes and pathways relevant to the pathogenesis of retinal diseases.
Reference: J Ocul Pharmacol Ther. 2022 Sep;38(7):513-526. https://pubmed.ncbi.nlm.nih.gov/35731128/
In vivo activity:
Thus far, no serious ocular or systemic adverse events have been attributed to risuteganib in patients with dry AMD and diabetic macular edema. However, these results are based on two phase 2 trials with a limited number of subjects with no long-term data available.
Reference: Expert Opin Investig Drugs. 2020 Jun;29(6):547-554. https://pubmed.ncbi.nlm.nih.gov/32349559/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
751.69
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Shao Z, Chwa M, Atilano SR, Park J, Karageozian H, Karageozian V, Kenney MC. The Transcriptome Profile of Retinal Pigment Epithelium and Müller Cell Lines Protected by Risuteganib Against Hydrogen Peroxide Stress. J Ocul Pharmacol Ther. 2022 Sep;38(7):513-526. doi: 10.1089/jop.2022.0015. Epub 2022 Jun 22. PMID: 35731128; PMCID: PMC9508878.
2. Yang P, Shao Z, Besley NA, Neal SE, Buehne KL, Park J, Karageozian H, Karageozian V, Ryde IT, Meyer JN, Jaffe GJ. Risuteganib Protects against Hydroquinone-induced Injury in Human RPE Cells. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):35. doi: 10.1167/iovs.61.10.35. PMID: 32818234; PMCID: PMC7443126.
3. Shaw LT, Mackin A, Shah R, Jain S, Jain P, Nayak R, Hariprasad SM. Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema. Expert Opin Investig Drugs. 2020 Jun;29(6):547-554. doi: 10.1080/13543784.2020.1763953. Epub 2020 May 13. PMID: 32349559.
In vitro protocol:
1. Shao Z, Chwa M, Atilano SR, Park J, Karageozian H, Karageozian V, Kenney MC. The Transcriptome Profile of Retinal Pigment Epithelium and Müller Cell Lines Protected by Risuteganib Against Hydrogen Peroxide Stress. J Ocul Pharmacol Ther. 2022 Sep;38(7):513-526. doi: 10.1089/jop.2022.0015. Epub 2022 Jun 22. PMID: 35731128; PMCID: PMC9508878.
2. Yang P, Shao Z, Besley NA, Neal SE, Buehne KL, Park J, Karageozian H, Karageozian V, Ryde IT, Meyer JN, Jaffe GJ. Risuteganib Protects against Hydroquinone-induced Injury in Human RPE Cells. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):35. doi: 10.1167/iovs.61.10.35. PMID: 32818234; PMCID: PMC7443126.
In vivo protocol:
1. Shaw LT, Mackin A, Shah R, Jain S, Jain P, Nayak R, Hariprasad SM. Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema. Expert Opin Investig Drugs. 2020 Jun;29(6):547-554. doi: 10.1080/13543784.2020.1763953. Epub 2020 May 13. PMID: 32349559.
1: Samanta A, Aziz AA, Jhingan M, Singh SR, Khanani AM, Chhablani J. Emerging Therapies in Nonexudative Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). 2021 Jan 28. doi: 10.1097/APO.0000000000000355. Epub ahead of print. PMID: 33512911.
2: Schneider K, Chwa M, Atilano SR, Shao Z, Park J, Karageozian H, Karageozian V, Kenney MC. Differential effects of risuteganib and bevacizumab on AMD cybrid cells. Exp Eye Res. 2021 Feb;203:108287. doi: 10.1016/j.exer.2020.108287. Epub 2020 Oct 16. PMID: 33075294.
3: Yang P, Shao Z, Besley NA, Neal SE, Buehne KL, Park J, Karageozian H, Karageozian V, Ryde IT, Meyer JN, Jaffe GJ. Risuteganib Protects against Hydroquinone-induced Injury in Human RPE Cells. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):35. doi: 10.1167/iovs.61.10.35. PMID: 32818234; PMCID: PMC7443126.
4: Bhatwadekar AD, Kansara V, Luo Q, Ciulla T. Anti-integrin therapy for retinovascular diseases. Expert Opin Investig Drugs. 2020 Sep;29(9):935-945. doi: 10.1080/13543784.2020.1795639. Epub 2020 Sep 9. PMID: 32657172.
5: Shaw LT, Mackin A, Shah R, Jain S, Jain P, Nayak R, Hariprasad SM. Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema. Expert Opin Investig Drugs. 2020 Jun;29(6):547-554. doi: 10.1080/13543784.2020.1763953. Epub 2020 May 13. PMID: 32349559.
